Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $511.97, generating $4.86 million. Her remaining stake totaled 324,443 shares, valued at approximately $166.1 million.
- United Therapeutics beat quarterly EPS expectations, reporting $7.27 versus the $6.86 consensus, although revenue of $783.3 million fell short of estimates and declined 1.9% year over year.
- Analysts maintain a “Moderate Buy” consensus with an average price target of $646, while institutional investors own approximately 94.08% of the company’s stock.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $511.97, for a total value of $4,863,715.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at $166,105,082.71. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
United Therapeutics Price Performance
Shares of UTHR stock opened at $518.53 on Wednesday. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35. The company has a market cap of $22.24 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 1.74 and a beta of 0.59. The stock has a 50 day simple moving average of $531.75 and a 200-day simple moving average of $538.30.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to analysts' expectations of $804.65 million. During the same quarter last year, the company earned $6.41 EPS. The firm's revenue for the quarter was down 1.9% compared to the same quarter last year. Analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on UTHR shares. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a report on Thursday, August 6th. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research note on Thursday, July 23rd. Bank of America reduced their price target on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. TD Cowen reaffirmed a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Wells Fargo & Company upgraded United Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $646.00.
Get Our Latest Stock Analysis on United Therapeutics
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System grew its holdings in shares of United Therapeutics by 55,526.2% during the second quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company's stock worth $18,036,953,000 after buying an additional 33,229,108 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of United Therapeutics in the second quarter valued at about $2,868,735,000. Wellington Management Group LLP raised its position in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock valued at $1,189,617,000 after buying an additional 1,042,711 shares during the last quarter. Jupiter Topco LLC purchased a new position in shares of United Therapeutics in the second quarter worth about $450,140,000. Finally, Norges Bank acquired a new position in United Therapeutics during the fourth quarter worth about $293,418,000. Hedge funds and other institutional investors own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
